Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 7;25(23):13164.
doi: 10.3390/ijms252313164.

Molecular Pathway and Immune Profile Analysis of IPMN-Derived Versus PanIN-Derived Pancreatic Ductal Adenocarcinomas

Affiliations

Molecular Pathway and Immune Profile Analysis of IPMN-Derived Versus PanIN-Derived Pancreatic Ductal Adenocarcinomas

Margaret A Park et al. Int J Mol Sci. .

Abstract

Intraductal papillary mucinous neoplasms (IPMN) are commonly detected pancreatic cysts that may transform into pancreatic ductal adenocarcinoma (PDAC). Predicting which IPMNs will progress to PDAC remains a clinical challenge. Moreover, identifying those clinically evident IPMNs for which a surveillance approach is best is a dire clinical need. Therefore, we aimed to identify molecular signatures that distinguished between PDAC with and without clinical evidence of an IPMN to identify novel molecular pathways related to IPMN-derived PDAC that could help guide biomarker development. Data from the Oncology Research Information Exchange Network (ORIEN) multi-institute sequencing project were utilized to analyze 66 PDAC cases from Moffitt Cancer Center and The Ohio State University Wexner Medical Center, for which tumor whole transcriptome sequencing datasets were generated. Cases were classified based on whether a tumor had originated from an IPMN (n = 16) or presumably through the pancreatic intraepithelial neoplasia (PanIN) pathway (n = 50). We then performed differential expression and pathway analysis using Gene-Set Enrichment Analysis (GSEA) and Pathway Analysis with Down-weighted Genes (PADOG) algorithms. We also analyzed immune profiles using the Tumor-Immune Microenvironment Deconvolution web portal for Bulk Transcriptomics (TIMEx). Both GSEA and TIMEx indicate that PanIN-derived PDAC tumors enrich inflammatory pathways (complement, hedgehog signaling, coagulation, inflammatory response, apical surface, IL-2/STAT5, IL-6/STAT3, EMT, KRAS signaling, apical junction, IFN-gamma, allograft rejection) and are comparatively richer in almost all immune cell types than those from IPMN-derived PDAC. IPMN-derived tumors were enriched for metabolic and energy-generating pathways (oxidative phosphorylation, unfolded protein response, pancreas beta cells, adipogenesis, fatty acid metabolism, protein secretion), and the most significantly upregulated genes (padj < 0.001) included mucin 2 (MUC2) and gastrokine-2 (GKN2). Further, the metabolic-linked gene signature enriched in the IPMN-derived samples is associated with a cluster of early-stage and long-survival (top 4th quartile) PDAC cases from The Cancer Genome Atlas (TCGA) expression database. Our data suggest that IPMN-derived and PanIN-derived PDACs differ in the expression of immune profiles and metabolic pathways. These initial findings warrant validation and follow-up to develop biomarker-based strategies for early PDAC detection and treatment.

Keywords: IPMN; PanIN; pancreatic ductal adenocarcinoma; transcriptomics.

PubMed Disclaimer

Conflict of interest statement

S.R.M. is a consultant for C2/Pentax and Steris, which are not related to the current work. All other authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of all eligible samples analyzed. Sample types are denoted in red font. A total of 66 samples were included in the analytic dataset (16 IPMN-derived and 50 PanIN-derived tumors). Abbreviations: FFPE, formalin-fixed paraffin-embedded; QC, quality control; MCC, Moffitt Cancer Center; and OSU, The Ohio State University.
Figure 2
Figure 2
Expression profiles differ between IPMN- and PanIN-derived tumors. Figure 2 shows a volcano plot of differential expression (x-axis) for IPMN-derived versus PanIN-derived tumors. PanIN-derived tumors were used as the reference and thus have negative fold change values.
Figure 3
Figure 3
PanIN-derived tumors are enriched for genes in inflammatory pathways, whereas IPMN-derived tumors are enriched for genes in energy production/metabolism pathways. (A,B) Bar graph of the normalized enrichment score (NES) on the x-axis versus the GSEA “Hallmark” pathways (A) or immune cell signatures (B) on the y-axis. Gene sets with a p-value of >0.05 are excluded.
Figure 4
Figure 4
IPMN-derived metabolic gene sets cluster in The Cancer Genome Atlas data with Stage I and low-grade tumors: Heatmaps showing patient samples (y-axis) and genes in IPMN-derived and non-IPMN-derived gene sets (x-axis). Hierarchical clustering was performed on gene sets. Patients were annotated based on disease-specific survival (DSSurvival, based on quartiles), stage (AJCC), and grade (1, 2, 3, 4 or not graded (GX)).

References

    1. Tonini V., Zanni M. Pancreatic cancer in 2021: What you need to know to win. World J. Gastroenterol. 2021;27:5851–5889. doi: 10.3748/wjg.v27.i35.5851. - DOI - PMC - PubMed
    1. McGuigan A., Kelly P., Turkington R.C., Jones C., Coleman H.G., McCain R.S. Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes. World J. Gastroenterol. 2018;24:4846–4861. doi: 10.3748/wjg.v24.i43.4846. - DOI - PMC - PubMed
    1. [(accessed on 10 June 2024)]. Available online: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts....
    1. Siegel R.L., Giaquinto A.N., Jemal A. Cancer statistics, 2024. CA Cancer J. Clin. 2024;74:12–49. doi: 10.3322/caac.21820. - DOI - PubMed
    1. Rahib L., Smith B.D., Aizenberg R., Rosenzweig A.B., Fleshman J.M., Matrisian L.M. Projecting cancer incidence and deaths to 2030: The unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–2921. doi: 10.1158/0008-5472.CAN-14-0155. - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources